FDA Finalizes Guidance on Distribution of Reprints

The FDA recently finalized its Good Reprint Practices for the Distribution of Medical Journal Articles. This article outlines the major provisions of the guidance and helps you learn how to make it work for your company.

The Future of DTC Advertising

Experts don't know if it's the economy, lack of new drugs in pharma's pipeline, or the new pro-regulation political climate, but 2009 is shaping up to be the year that direct-to-consumer (DTC) advertising will suffer a round of budget cuts and setbacks not seen in a long time. We poll readers and experts to help predict the immediate future of DTC advertising and to get some insights from experts.

Pharma Marketers Dive Deeper Into Social Media: The Good, the Bad, & the Ugly...

This article focuses in some detail on three interesting pharma social media initiatives: (1) Procter & Gamble's Asacol Community for Ulcerative Colitis Patients; (2) Novo Nordisk's Levemir-branded Race With Insulin Twitter account; and (3) UCB's sponsored epilepsy community on the PatientsLikeMe website.

Sales Force Effectiveness Metrics: More Important Than Ever in a Tough Market

This article summarizes a recent discussion between eyeforpharma's Editor Lisa Roner and Hans Nagl, Promotion Response Modelling Manager, Shire, about how the current economy and changing pharma landscape is impacting program effectiveness measures.

Pharma-Sponsored Medical Ghostwriting

Pharma Marketing News surveyed readers to determine if medical journal articles sponsored and ghostwritten by drug companies are a legitimate part of marketing to physicians and to get opinions on various other issues raised in the press about ghostwriting.

Ramifications of FDA Regulatory Actions: Helping FDA Find a New Media Regulatory Pathway

Arnold Friede, counsel to the law firm McDermott Will & Emery LLP, and former Senior Counsel at Pfizer, believes that there is an opportunity now to make a strong and compelling argument for the adoption of rational regulatory policies by the FDA that address the unique features not only of sponsored links, but of other kinds of new communication tools, such as social media.

Pharma’s Bad Rep or Bad Rap: Whatever! The Drug Industry Must Earn Back the...

This article summarizes the results of the 'How to Earn Back the Public's Trust' survey hosted by Pharma Marketing News between February 4, 2009 and March 14, 2009 , including selected comments from respondents and other commentators.

FDA’s Use of Social Media: Peanuts Today, Drugs Tomorrow!

In the future, will the FDA also be pulled into social media by a major Rx drug recall? What can the drug industry learn from the FDA's use of social media and will FDA's example help guide the industry toward best practices in this area? This article describes FDA's social networking initiatives in context of these questions.

Developing Guidelines for Pharma’s Use of the Internet & Social Media: Whatever! A Call...

Shouldn't we make sure that when it comes time for the FDA to actually create a guidance document on social media that it does it with input from ALL stakeholders? Survey results.

Social Media Adverse Event Reporting Safe Harbors: It’s Time for FDA to Open Up...

This article presents ideas for regulatory 'safe harbors' under which pharmaceutical companies would be relieved of the responsibility of monitoring social media for adverse events. Includes a detailed summary of responses to the survey 'FDA Regulation of Drug & Device Promotion via the Internet & Social Media' regarding social media adverse event monitoring, processing, challenges, and uncertainties.
- Advertisement -